May 6, 2018

Gina Haspel wanted to withdraw nomination to lead CIA

Haspel at Mike Pompeo's swearing in as Secretary of State. Photo: Mandel Ngan/AFP via Getty Images

Gina Haspel, President Trump's nominee to succeed Mike Pompeo as CIA director, wanted to withdraw her name from consideration amid concerns that her role in enhanced interrogation of suspected terrorists would derail with her confirmation, Axios has confirmed, per a source with direct knowledge. The story was first reported by The Washington Post.

The details: During a West Wing meeting with White House officials on Friday, Haspel indicated that she planned to withdraw to avoid "the spectacle of a brutal confirmation hearing," per the Post. That prompted press secretary Sarah Sanders and legislative affairs director Marc Short to head to CIA headquarters to convince her to keep her name in consideration.

  • "Amid the questioning in the West Wing on Friday afternoon, Haspel told White House aides she did not want her nomination to harm the CIA. She also feared unfair attacks on her own reputation, saying that she didn’t want to be 'the next Ronny Jackson,' one official said."
  • "Trump learned of the drama Friday, calling officials from his trip to Dallas. He decided to push for Haspel to remain as the nominee after initially signaling he would support whatever decision was taken, administration officials said."
  • "Short ... told Haspel she could still be confirmed despite the information that had recently come to attention of the White House — and the administration expected some Democrats to support her, officials said."

Go deeper: Meet Gina Haspel ... The CIA's history with "black sites" and "enhanced interrogation."

Get more stories like this by signing up for our weekly political lookahead newsletter, Axios Sneak Peek. 

Go deeper

Peter Navarro defends hydroxychloroquine use in heated CNN interview

White House economic adviser Peter Navarro defended the use of anti-malarial drug hydroxychloroquine to treat coronavirus during a CNN interview Monday, highlighting "the possibility" that it has therapeutic efficacy.

Why it matters: Navarro did not deny reporting from Axios' Jonathan Swan that he got into a heated exchange in the White House Situation Room over the weekend with infectious disease expert Dr. Anthony Fauci about the drug's prospects against the illness.

Special report: Health care workers vs. coronavirus

Photo Illustration: Sarah Grillo/Axios. Photos: Angela Weiss/AFP via Getty Images, Bruce Bennett/Getty Images, and Europa Press News/Europa Press via Getty Images

Health care workers are at an especially high risk of catching the coronavirus, because of their prolonged exposure to patients who have it. Making matters worse, the U.S. doesn't have enough of the protective equipment, like masks and gloves, that keeps them safe.

  • And yet these workers, with loved ones of their own, keep showing up at hospitals across the country, knowing that more Americans than they can possibly care for are depending on them.
Go deeperArrow49 mins ago - Health

Backed by the Fed, bond investors get bullish

Illustration: Sarah Grillo/Axios

The Fed's massive injections of liquidity have reopened much of the bond market, and after back-to-back weeks in which more than $100 billion flowed out of bond funds, investors have regained their bearings and now see opportunity.

What's happening: But after the hemorrhaging outflows relented last week, bulls may now be sticking their heads out a bit too far. Junk bond funds took in more than $7 billion for the week ended April 1, according to Refinitiv Lipper, setting a new weekly record.